title: Disposition of the cholesterol absorption inhibitor ezetimibe in mdr1a/b (-/-) mice.
abstract: The lipid lowering agent ezetimibe (EZ) and its intestinally formed glucuronide (GLUC) were shown to be substrates of the efflux transporters P-glycoprotein (P-gp) and the multidrug resistance associated protein 2 (MRP2) which markedly influences the disposition and efficacy of EZ in man. This study aims to elucidate the unique meaning of P-gp in the pharmacokinetics of EZ in mice. In brief, serum concentrations, organ distribution and elimination of EZ were determined in 10 male wild-type and mdr1a/b (-/-) mice after oral treatment with EZ (10 mg/kg, 10 days). EZ and GLUC were quantified in serum, urine, feces and various tissues using a validated LC-MS/MS method. Compared to wild-type mice, mdr1a/b knockout was associated with significantly increased serum concentrations of GLUC (5.58 +/- 2.07 versus 2.09 +/- 0.83 ng/ml, p < 0.001) but not of EZ (0.92 +/- 0.73 versus 0.55 +/- 0.40 ng/ml, n.s.). Consequently, urinary excretion of GLUC was about three-fold increased (9.96 +/- 0.27 versus 3.10 +/- 1.37 microg/day, p = 0.049) whereas renal clearance and the amount excreted via feces remained unchanged. Both EZ and GLUC were not over-proportionally distributed into investigated organs. P-glycoprotein primary influences the oral absorption of ezetimibe in mice. Distribution, renal and fecal excretion of the drug seems not to be markedly affected by P-glycoprotein.
authors.affiliation: Department of Clinical Pharmacology, University of Greifswald, Friedrich-Loeffler-Strasse 23d, Greifswald, Germany. stefan.oswald@uni-greifswald.de
authors.forename: Stefan
authors.initials: S
authors.lastname: Oswald
authors.forename: Christiane
authors.initials: C
authors.lastname: Koll
authors.forename: Werner
authors.initials: W
authors.lastname: Siegmund
mesh_terms: D018435:ATP Binding Cassette Transporter, Subfamily B / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D018528:ATP-Binding Cassette Transporters / Q000235:genetics / Q000378:metabolism*; D000284:Administration, Oral; D000818:Animals; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D001384:Azetidines / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics* / Q000652:urine; D001682:Biological Availability; D001711:Biotransformation; D002784:Cholesterol / Q000378:metabolism*; D000069438:Ezetimibe; D005243:Feces / Q000737:chemistry; D020719:Glucuronides / Q000378:metabolism; D007408:Intestinal Absorption / Q000187:drug effects*; D007668:Kidney / Q000378:metabolism; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D014018:Tissue Distribution; D000097202:ATP-Binding Cassette Sub-Family B Member 4